Community protocol
Third-partyDSIP 10mg
- 01Reconstitution solution
- 1 mL
- 02Dose
- 1 mg
- 03Syringe units
- 10 units
- 04Frequency
- As needed
- 05Cycle length
- Not specified
- 06Bacteriostatic water
- 1 mL
- 07Bottle size
- 10 mg
- 08Bottles needed
- Not specified
DSIP
A nine-amino-acid peptide isolated from rabbit brain in 1977 and named for the sleep pattern it induced. The human sleep evidence has never been convincing.
Overview
DSIP was found by taking blood from rabbits in induced sleep and isolating the fraction that put other rabbits to sleep. It was named for that effect. Fifty years later, its receptor has still not been identified, its physiological role is unclear, and human studies of sleep have produced small and inconsistent results. Some of the more interesting human work is not about sleep at all but about opioid and alcohol withdrawal.
A nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from cerebral venous blood of rabbits in electrically induced sleep. No specific receptor has been characterised, and it is not established as a bona fide neurotransmitter or neuromodulator. Reported effects across the literature include modulation of delta-wave EEG activity, altered corticotropin and somatotropin release, and antinociception, with considerable inconsistency between groups. Small human studies in chronic insomnia showed limited effect; more consistent findings come from small trials in opiate and alcohol withdrawal syndromes.
Research areas
Sleep architectureOpiate withdrawalStress response
Community-specified data
Community dosage information
Not medical guidance. These third-party figures have not been independently verified, clinically reviewed, or endorsed by DB Peptide. They may be inaccurate or unsafe and should not replace product labelling or advice from a qualified clinician.
Dosing reported in the literature
Every protocol below is reproduced from a published study or approved labelling, with its source named. These are records of what was studied — not recommendations, and not a suggestion that any of them is appropriate for any person.
| Protocol as reported | Source |
|---|---|
| 25 mcg/kg intravenously daily for 5 days in opiate withdrawal | Dick et al., European Neurology 1980s series |
| Single intravenous doses in chronic insomnia with polysomnographic endpointsEffects on objective sleep measures were small and inconsistent. | Schneider-Helmert, Neuropsychobiology 1980s |
Trial status
Small human studies from the 1980s and 1990s in insomnia and withdrawal syndromes. No modern controlled programme.
Reported safety signals
- Human exposure data is limited to small studies conducted decades ago.
- No receptor has been identified, so off-target effects cannot be predicted from mechanism.
- Sold through unregulated channels; identity and purity are unverified.
Common questions
Does DSIP actually help with sleep?
The name is more convincing than the data. The peptide was named for an effect observed in rabbits; controlled human studies with polysomnography showed small and inconsistent changes, and there has been no rigorous modern trial to settle it.
Primary sources
Medical disclaimer
This page is for informational and research purposes only. Nothing here constitutes medical advice. The compounds discussed are research chemicals. Consult a qualified clinician before starting any protocol.
How this profile was built →